10x Genomics Unveils Atera and Sets a New Bar for Spatial Biology at Scale

In an exclusive conversation ahead of SynBioBeta 2026 on May 4-7th in San Jose, the team at 10x Genomics is framing the next era of biology as one that can finally be measured at single-cell sensitivity, inside intact tissue, across hundreds of cells at a time. That ambition arrived with a product on April 18th, when the company introduced Atera at the AACR Annual Meeting in San Diego. Atera is an in situ spatial biology platform engineered for whole-transcriptome spatial analysis at scales that were previously out of reach, and it marks 10x's boldest move yet in a strategy to reshape how researchers analyze cells.

Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, 10x has grown into one of the most influential toolmakers in modern biology, with a market capitalization of nearly $2.5 billion and annual revenue of around $600 million. Chromium, launched in 2016, opened single-cell gene expression to tens of thousands of cells per run. It later expanded into spatial biology with its Visium and Xenium platforms, extending its ability to measure not only individual cells but their organization within tissue. Atera is the next step change in measuring what remains difficult to quantify in biology.

"Biology is inherently complex, and as much progress as we have made, we still understand only a fraction of how it works. Progress in medicine depends on confronting that complexity directly, which requires measuring biology as it actually functions," said Serge Saxonov, Chief Executive Officer and Co-founder of 10x Genomics.

The platform itself is built for numbers that have, until now, sat out of reach. Atera runs up to 800 whole-transcriptome samples per year on a single instrument at 1 square centimeter each, with targeted assays scaling into the thousands. It detects thousands of transcripts per cell in human FFPE tissue and more than ten thousand per cell in cell lines, handling both fresh-frozen and FFPE formats. 10x is pairing the hardware with a new cloud analysis layer built on the foundation of Xenium Explorer, bringing GPU-accelerated analysis into the web while letting researchers route data to 10x Cloud, customer-managed cloud infrastructure, or on-premise storage.

"We rethought the system from the ground up, optimizing each component across chemistry, hardware and software to enable what was previously impossible in spatial analysis," said Michael Schnall-Levin, Chief Technology Officer, Chief Strategy Officer, and Founding Scientist at 10x Genomics.

Early access partners are already turning those claims into data. The Allen Institute, Brigham and Women's Hospital, and the German Cancer Research Center ran the platform ahead of launch, and DKFZ data presented at AACR showed Atera detecting active and diverse immune populations inside colorectal tumors previously classified as having limited infiltration, a finding that could reshape assumptions baked into years of cancer biology. Commercial adoption is moving in parallel. Macrogen, alongside its US subsidiary Psomagen, has committed to deploying multiple Atera instruments as the first global CRO on the platform. Bioptimus, which is building the STELA spatial atlas to power its M-Optimus multimodal AI model, plans to expand from Xenium to Atera in 2027 as its program scales, and partners including the Broad Clinical Labs and the Translational Genomics Research Institute have flagged the combination of throughput and sensitivity as what they need for the next wave of biomarker and clinical studies.

"It was surprising to see that whole-transcriptome profiling could be achieved at this level of sensitivity, and we believe Atera has the potential to transform the field," said Hongkui Zeng, Executive Vice President and Director of Brain Science at the Allen Institute.

Pre-orders are open, shipping begins in the second half of 2026, and 10x has launched Catalyst Research Services so that labs without an instrument can still submit samples for whole-transcriptome spatial analysis. For the founders, investors, and platform builders heading to San Jose in May, the pitch is straightforward. The AI-driven drug discovery engines, virtual-cell efforts, and clinically linked spatial atlases taking shape across the industry all depend on a measurement layer that can keep up. With Atera, 10x is betting it can be that layer.